Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

677
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
677
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

405
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
405
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

473
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
473
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

306
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
306
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

513
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
513

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebrovascular Diagnoses During First Recorded Pregnancies in a 17-Year Period-A Nationwide Analysis of Healthcare Administrative Records Between 2004 and 2020 in a Central-Eastern European Population.

Epidemiologia (Basel, Switzerland)·2026
Same author

MRI Diffusion Tensor Image Analysis Along the Perivascular Space: Effects of Mean Tract Orientation Divergence.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Reply to: "Alcohol Intake and Parkinson's Symptoms Following Diagnosis".

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Asundexian for Secondary Stroke Prevention.

The New England journal of medicine·2026
Same author

Concomitant Dysregulation of Cerebral Vasoreactivity and Arterial Blood Pressure Is Closely Related in Patients with Carotid Stenosis.

Life (Basel, Switzerland)·2026
Same author

[Awards of Hungarian neurology and their awardees: 1936-2025].

Ideggyogyaszati szemle·2026

Related Experiment Video

Updated: Nov 9, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.6K

Trimetazidine Use in Parkinson's Disease: Is It a Resolved Problem?

Dávid Pintér1, Dániel Bereczki2,3, András Ajtay2,3

  • 1Department of Neurology, Medical School, University of Pécs, Pécs, Hungary 7623 david_pinter@outlook.com.

Eneuro
|April 17, 2021
PubMed
Summary

European Medicines Agency (EMA) recommendations to avoid trimetazidine (TMZ) in Parkinson's disease (PD) led to a modest decrease in TMZ use in Hungary. The reduction was primarily due to increased discontinuation, not fewer new prescriptions, indicating moderate effectiveness.

Keywords:
European Medicines AgencyParkinson’s diseaseangina pectorisinterrupted time series analysistrimetazidine

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K

Related Experiment Videos

Last Updated: Nov 9, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.6K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Neurology
  • Health Policy Analysis

Background:

  • Trimetazidine (TMZ), an antianginal medication, is known to potentially exacerbate movement disorders.
  • The European Medicines Agency (EMA) advised against its use in Parkinson's disease (PD) patients due to this risk.
  • Understanding the real-world impact of such regulatory recommendations is crucial for patient safety.

Purpose of the Study:

  • To evaluate the effect of EMA recommendations on trimetazidine (TMZ) prescription trends in Parkinson's disease (PD) patients in Hungary.
  • To analyze changes in TMZ utilization patterns following the EMA's 2010 advisory.
  • To determine the primary drivers (discontinuation vs. new prescriptions) of any observed changes in TMZ use.

Main Methods:

  • Nationwide retrospective study utilizing health administrative data from Hungary (2010-2016).
  • Interrupted time series analysis to assess trends in TMZ use before and after the EMA recommendation.
  • Statistical analysis of prescription data, including discontinuation rates and new prescriptions.

Main Results:

  • A significant decrease in TMZ use among PD patients was observed post-EMA recommendation, with a trend of -6.56% every six months.
  • The primary driver for reduced TMZ use was an increased rate of discontinuation, rather than a significant reduction in new prescriptions.
  • Despite recommendations, a considerable proportion (40%) of TMZ use was off-label, and the drug remained in use for both on- and off-label indications.

Conclusions:

  • EMA recommendations had a moderately effective impact on reducing trimetazidine (TMZ) use in Parkinson's disease (PD) patients in Hungary.
  • Increased discontinuation rates, not a decrease in new prescriptions, accounted for the observed decline in TMZ utilization.
  • Continued use of TMZ in PD patients, including for off-label purposes, highlights the need for ongoing monitoring and adherence to safety guidelines.